Prostate Cancer – Unmet Need – Detailed, Expanded Analysis – Metastatic Hormone Sensititve (US/EU)
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer has evolved in recent years with the approval of hormonal agents such as Zytiga (Janssen), Xtandi (Pfizer / Astellas), and the next-generation androgen receptor inhibitor Erleada (Janssen). In December 2020, Orgovyx (Myovant / Takeda) was FDA approved and has also entered the treatment paradigm. Although novel treatment modalities have improved patient outcomes, substantial unmet need remains for novel therapies with better efficacy and improved safety and tolerability. Therefore, the therapeutic management of newly diagnosed metastatic hormone-sensitive prostate cancer presents an enormous commercial opportunity for drug developers.
QUESTIONS ANSWERED
What treatment drivers and goals are most likely to influence the choice of therapy for newly diagnosed metastatic hormone-sensitive prostate cancer?
What attributes are key influencers of prescribing, and what are the hidden opportunities for drug developers?
What are the prevailing areas of unmet need and opportunity in this patient population?
What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical therapy for newly diagnosed metastatic hormone-sensitive prostate cancer?
DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by our experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in June 2021.
Prostate Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Hormone Sensititve (US/EU)
Executive Summary
Unmet Need - Metastatic Hormone-Sensitive Prostate Cancer - Executive Summary - October 2021
Introduction
Overview
Methodology
Rationale for Treatment Drivers and Goals Selection
Rationale for Drug Selection
Products for Metastatic Hormone-Sensitive Prostate Cancer and Rationale for Drug Selection
Treatment Drivers and Goals
Key Findings: Attribute Importance
Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer
Importance of Efficacy Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: United States
Importance of Efficacy Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: Europe
Importance of Safety and Tolerability Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: United States
Importance of Safety and Tolerability Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: Europe
Importance of Convenience of Administration Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: United States
Importance of Convenience of Administration Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: Europe
Key Findings: Stated vs. Derived Importance
Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: United States
Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Metastatic Hormone-Sensitive Prostate Cancer: Europe
Product Performance Against Treatment Drivers and Goals
Key Findings
Overall Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer: United States
Overall Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Europe
Mean Overall Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer: United States and Europe
Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Efficacy Attributes: United States
Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Efficacy Attributes: Europe
Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Safety and Tolerability Attributes: United States
Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Safety and Tolerability Attributes: Europe
Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Convenience of Administration Attributes: United States
Relative Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer Across Select Convenience of Administration Attributes: Europe
Assessment of Unmet Need
Key Findings: Unmet Need in Metastatic Hormone-Sensitive Prostate Cancer
Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Metastatic Hormone-Sensitive Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Metastatic Hormone-Sensitive Prostate Cancer: United States
Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Metastatic Hormone-Sensitive Prostate Cancer: Europe
Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Metastatic Hormone-Sensitive Prostate Cancer: United States
Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Metastatic Hormone-Sensitive Prostate Cancer: Europe
Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Metastatic Hormone-Sensitive Prostate Cancer: United States
Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Metastatic Hormone-Sensitive Prostate Cancer: Europe
Key Findings: Unmet Need in Metastatic Hormone-Sensitive Prostate Cancer and Related Indications
Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Metastatic Hormone-Sensitive Prostate Cancer and Related Indications: United States
Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Metastatic Hormone-Sensitive Prostate Cancer and Related Indications: Europe
Opportunity Analysis
Areas of Opportunity in the Metastatic Hormone-Sensitive Prostate Cancer Market and Emerging Therapy Insights
Opportunity: A New Therapy That Can Prolong Overall Survival
Opportunity: A New Therapy That Delays Disease Progression and Skeletal-Related Events
Opportunity: A Novel Agent That Improves the Prostate-Specific Antigen Response Rate
Opportunity: A Novel Therapy With Improved Safety and Tolerability
Target Product Profiles
Assessing Drug Development Opportunities
Target Product Profile Methodology
Attributes and Attribute Levels
Assigned Prohibitions for the Conjoint Module
Attribute Importance and Part-Worth Utilities
Metastatic Hormone-Sensitive Prostate Cancer Target Product Profile: Attribute Importance
Median Overall Survival (months)
Median Radiographic Progression-Free Survival (months)
Median Time to Skeletal-Related Events (months)
Incidence of Grade 3/4 Hypertension (% of patients)
Incidence of Any Grade Fatigue (% of patients)
Incidence of Any Grade Rash (% of patients)
Price per 28-Day Cycle ($)
Conjoint Analysis-Based Simulation of a Market Scenario
Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Target Product Profiles Included in the Market Scenario